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LETTERS TO THE EDITOR
Anemia and Poor
Prognosis in Advanced Heart Failure
I read with great interest the study by Horwich et al. (1) on the
association of anemia with poor prognosis in advanced heart
failure. The investigators observed that mortality decreased in
linear fashion as hemoglobin level increased without excess mor-
tality at the highest hemoglobin level. However, hemoglobin level
17 g/dl was seen in only 3% of men and 1% of women. Thus, the
small number of patients at high hemoglobin level could have
limited the investigators’ ability to observe a U-shaped relation-
ship.
The percentage of patients with chronic obstructive lung disease
who are the most likely candidates to have high hemoglobin were
not listed in the report. I would appreciate the investigators’
comments.
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REPLY
We appreciate Dr. Ghali’s interest in our recent investigation of
the relationship between hemoglobin (Hb) level and mortality in
patients with advanced heart failure (HF) (1). We fully agree with
Dr. Ghali that our ability to detect excess mortality in HF patients
with above-normal Hb levels is limited by the small number of
patients in this population. The issue of optimal Hb levels in HF
and the possibility of a U-shaped relationship with regard to
mortality is increasingly important, as interest grows in correcting
anemia in HF using erythropoietin or newer analogues.
Prospective epidemiological studies such as the Framingham
Heart Study have demonstrated a U-shaped relationship between
hematocrit and mortality due to cardiovascular disease (2). A
preliminary analysis of elderly patients with mild to moderate HF
enrolled in the Evaluation of Losartan In The Elderly (ELITE) II
study showed a U-shaped relationship, with higher mortality seen
in men with hemoglobin levels 16.5 g/dl and in women with
hemoglobin levels 15.5 g/dl (3). It is interesting to note,
however, that an analysis of patients with mild to moderate HF in
the Studies Of Left Ventricular Dysfunction (SOLVD) database
failed to find a U-shaped relationship between hematocrit and
mortality in HF (4). Male patients with a hematocrit of 40% to
49% (n  4,235) had a mortality rate similar to those with
hematocrit levels above 50% (n  344).
As Dr. Ghali points out, the highest Hb level would be expected
in patients with severe chronic obstructive pulmonary disease
(COPD). Unfortunately, we do not have data on rates of COPD
in our cohort, as it was not a variable in our original study design.
In our study and the analysis of the SOLVD database, only a small
proportion of patients with HF had elevated hemoglobin or
hematocrit levels. Analyses of HF populations that include pa-
tients with increased Hb levels secondary to COPD, congenital
heart disease, or polycythemia vera would make assigning relative
mortality risk of elevated Hb versus the primary disease process
leading to increased hemoglobin extremely difficult.
Initial reports on using erythropoietin in mild to moderately
anemic HF patients in order to raise Hb to at least 12.5 g/dl have
shown clinical benefit and no adverse effects (5). Conversely, a
randomized controlled trial in 1,233 patients with HF or ischemic
heart disease along with renal failure on hemodialysis showed a
trend for increased cardiovascular events in subjects randomized to
maintain a hemoglobin of 14 g/dl compared to those with a goal
of 10 g/dl (6). Further clinical trials are needed to definitively assess
whether raising hemoglobin is beneficial in HF and whether there is
an upper limit of hemoglobin level above which benefit is lost.
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Use of Term
“Non-Q Infarction” is Questioned
The recent study in JACC titled “Revisiting the Culprit Lesion in
Non–Q-Wave Myocardial Infarction” warrants comment (1). The
Journal of the American College of Cardiology Vol. 40, No. 12, 2002
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